K. Bulusu

发表

Community assessment of cancer drug combination screens identifies strategies for synergy prediction

Tin Chi Nguyen, Robert M. Vogel, M. Zaslavskiy, 2017, bioRxiv.

Abstract 3886: A large cancer pharmacogenomics combination screen powering crowd-sourced advancement of computational drug synergy predictions

J. Saez-Rodriguez, J. Guinney, M. Menden, 2018, Experimental and Molecular Therapeutics.

A cancer pharmacogenomic screen powering crowd-sourced advancement of drug combination prediction

Robert M. Vogel, M. Zaslavskiy, Y. Guan, 2018 .

Development of a Novel Azaspirane That Targets the Janus Kinase-Signal Transducer and Activator of Transcription (STAT) Pathway in Hepatocellular Carcinoma in Vitro and in Vivo*

Basappa, Julian E. Fuchs, A. Bender, 2014, The Journal of Biological Chemistry.

Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the drug target space for anticancer therapies

Andreas Bender, Tamás Korcsmáros, Péter Csermely, 2017, npj Systems Biology and Applications.

Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives.

Andreas Bender, Rajarshi Guha, Eugene Muratov, 2016, Drug discovery today.

Analysis of Differential Efficacy and Affinity of GABAA (α1/α2) Selective Modulators.

Julian E. Fuchs, R. M. Owen, R. Glen, 2016, Molecular pharmaceutics.

Novel Adamantanyl-Based Thiadiazolyl Pyrazoles Targeting EGFR in Triple-Negative Breast Cancer

Lewis H. Mervin, Basappa, Julian E. Fuchs, 2016, ACS omega.

Microwave-assisted synthesis, characterization and cytotoxic studies of novel estrogen receptor α ligands towards human breast cancer cells.

Basappa, Julian E. Fuchs, A. Bender, 2015, Bioorganic & medicinal chemistry letters.

A One Pot Synthesis of Novel Bioactive Tri-Substitute-Condensed-Imidazopyridines that Targets Snake Venom Phospholipase A2

Basappa, Julian E. Fuchs, A. Bender, 2015, PloS one.

MOLPRINT 2D-based identification and synthesis of novel chromene based small molecules that target PLA2: validation through chemo- and bioinformatics approaches

Lewis H. Mervin, Basappa, Julian E. Fuchs, 2015 .

Data types and resources

Khader Shameer, Krishna C. Bulusu, Stephanie Kay Ashenden, 2021 .

Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer

U. McDermott, A. Bornot, M. Ughetto, 2022, Nature Communications.

DeepSynergy: predicting anti-cancer drug synergy with Deep Learning

Andreas Bender, Sepp Hochreiter, Günter Klambauer, 2017, Bioinform..

Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study.

J. Barrett, M. Ahn, T. Mok, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

G. Mills, C. Caldas, J. Barrett, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

canSAR: an integrated cancer public translational research and drug discovery resource

Bissan Al-Lazikani, Mark D. Halling-Brown, Krishna C. Bulusu, 2011, Nucleic Acids Res..

Graph Neural Networks Including Sparse Interpretability pdf

Marylens Hernandez, Jonathan R. Dry, Krishna C. Bulusu, 2020, ArXiv.

Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen

Robert M. Vogel, M. Zaslavskiy, Y. Guan, 2019, Nature Communications.

Precision medicine

K. Bulusu, S. Deswal, P. Agapow, 2021, The Era of Artificial Intelligence, Machine Learning, and Data Science in the Pharmaceutical Industry.

Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen

Amir K. Foroushani, Yuanfang Guan, Jaewoo Kang, 2019, Nature Communications.

Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.

Ying Cheng, J. Barrett, S. Ramalingam, 2019, Journal of Clinical Oncology.

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

Jie Yang, J. Barrett, M. Ahn, 2023, Nature Communications.

Orthologue chemical space and its influence on target prediction

Andreas Bender, Ola Engkvist, Avid M. Afzal, 2017, Bioinform..

Drug Combination Modeling

Andreas Bender, Anna H.C. Vlot, Dan Mason, 2020 .

Knowledge Graph-based Recommendation Framework Identifies Novel Drivers of Resistance in EGFR mutant Non-small Cell Lung Cancer

U. McDermott, M. Ughetto, D. Polychronopoulos, 2021, bioRxiv.

11th German Conference on Chemoinformatics (GCC 2015)

Timothy Clark, Jonathan W. Essex, Peter Kolb, 2016, J. Cheminformatics.

canSAR: updated cancer research and drug discovery knowledgebase

Amanda C. Schierz, Costas Mitsopoulos, Albert A. Antolin, 2013, Nucleic Acids Res..

Comparison of classical tumour growth models for patient derived and cell-line derived xenografts using the nonlinear mixed-effects framework

K. Bulusu, J. Yates, Dimitrios Voulgarelis, 2022, Journal of biological dynamics.

Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors

J. Dry, K. Bulusu, Szabolcs Hetey, 2023, bioRxiv.